Product Information:

Active Ingredient:

Enemeez® Plus

Delivered Active Ingredient (in each tube)
Docusate Sodium 283mg……………………………………..Stool Softener
Benzocaine 20mg……………………………………………Topical Anesthetic
Inactive ingredients: Glycerine and Polyethylene Glycol.

Enemeez® Plus contains 20 mg of benzocaine, assisting in the anesthetization of the rectum and lower bowel. The formulation was developed for patients who experience Autonomic Dysreflexia or painful bowel movements. Enemeez® Plus should not be used when open sores are present. Autonomic dysreflexia (AD) is commonly caused by bladder distension, bowel distension, and defecation1. The fact that the associated hypertension may cause seizures, intracerebral hemorrhage, or death is of particular concern2. Clinically, Autonomic dysreflexia is characterized by:

  • A sudden increase in blood pressure with compensatory bradycardia.
  • Headache.
  • Profuse sweating and vasodilatation with skin flushing above the level of the spinal cord injury (SCI)3. Autonomic dysreflexia occurs in patients with a spinal cord injury above the Greater Splanchnic outflow, usually above T6.

Therapeutic Efficacy:

Enemeez® products are effective for bowel care needs associated with spinal cord injury and disease, multiple sclerosis, traumatic brain injury, spina bifida, long-term care, stroke and constipation. Adults and children 12 years of age and older (with adult supervision), one to three units daily. Enemeez® has been used successfully for over ten years in hundreds of Model System and CARF accredited facilities throughout the country. By implementing Enemeez® usage across your facilities, both patients and facility will benefit by the following:

  • Fast, predictable results typically in 2-15 minutes1, non-irritating formula. No afterburn.
  • Can reduce nursing intervention required for in-patient bowel care; can result in labor cost savings to the facility.2
  • Can assist in the improvement of patient care and FIM scores associated with bowel care.
  • Can assist in reducing time spent with patient for dressing/redressing due to episodes of incontinence or fecal discharge.2
  • Can virtually eliminate episodes of incontinence3. Can assist in reducing complications of wound contamination associated with perianal pressure ulcers.
  • No mucosal discharge3; helps to maintain healthy skin integrity.
  • Easy rectal usage for patients with reflex issues or nausea.
  • Can assist in reducing time missed in therapy/rehabilitation due to episodes of incontinence, prolonged bowel care, or fatigue.2
  • Can assist with facility savings on pads, laundry, gowns, sheets, etc. due to incontinence or fecal discharge.

Source: 1. Federal Register / Vol. 50, No. 10 / Tuesday, January 15, 1985 / Proposed Rules; pgs 2124-2158. 2. Rehabilitation Nursing (Dunn KL & Galka ML (1994) Comparison of the Effectiveness of Therevac SB and Bisacodyl Suppositories in SCI Patients Bowel Programs, Rehabil Nurs. 19 (6):334-8. 3. Alliance Labs In-house research. Customer Survey Nov. 6, 2009.


Order Samples